No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ORGO240517C2500
- 0.25
- +0.15+150.00%
15min DelayClose May 9 15:59 ET
0.25High0.25Low
0.25Open0.10Pre Close1 Volume222 Open Interest2.50Strike Price25.00Turnover249.92%IV20.61%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.25Time Value100Contract SizeAmericanOptions Type0.4745Delta0.4753Gamma9.12Leverage Ratio-0.0220Theta0.0002Rho4.33Eff Leverage0.0013Vega
Intraday
- 5D
- 1D
News
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript
Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript
Organogenesis (ORGO) Q1 2024 Earnings Call Transcript
Express News | Organogenesis Reaffirms 2024 Guidance; Sees Net Revenue $445M-$470M Vs $454.69M Est
Organogenesis Hldgs Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $109.976M Beat $101.050M Estimate
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is unchanged from the same period last year
Express News | Organogenesis Holdings Inc: Reaffirming Prior Guidance for 2024
Express News | Organogenesis Holdings Inc: Qtrly Shr Loss $0.02
Comments
$Organogenesis(ORGO.US$ revenue of $110.0 million for the first quarter of 2024, an increase
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
The implications of ReNu’s success extend far beyond symptom management.
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
$Organogenesis(ORGO.US$
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
1
2
Despite poor earnings, the high P/E ratio indicates investors anticipate strong future growth, justifying a higher stock price. Unless earnings significantly deteriorate, the share price should remain strong.
1
Read more